gr 89696 has been researched along with Breast Neoplasms in 1 studies
GR 89696: a potent & selective kappa opioid receptor agonist; RN given refers to (E)-2-butenedioate(1:1); RN for parent cpd not available 11/92; GR 103545 is the (R)-isomer
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although bone cancer-related pain is one of the most disruptive symptoms in patients with advanced cancer, patients are often refractory to pharmacological treatments; thus, more effective treatments for bone cancer pain are needed." | 1.37 | The intrathecally administered kappa-2 opioid agonist GR89696 and interleukin-10 attenuate bone cancer-induced pain through synergistic interaction. ( Cui, JH; Jeong, CW; Kim, WM; Kim, YO; Lee, SH; Yoon, MH, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, WM | 1 |
| Jeong, CW | 1 |
| Lee, SH | 1 |
| Kim, YO | 1 |
| Cui, JH | 1 |
| Yoon, MH | 1 |
1 other study available for gr 89696 and Breast Neoplasms
| Article | Year |
|---|---|
The intrathecally administered kappa-2 opioid agonist GR89696 and interleukin-10 attenuate bone cancer-induced pain through synergistic interaction.
Topics: Analgesics, Opioid; Animals; Anti-Inflammatory Agents; Behavior, Animal; Bone Neoplasms; Breast Neop | 2011 |